ACRS

Aclaris Therapeutics, Inc. (ACRS) | Rumor.io

Aclaris Therapeutics

ACRS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,175

Bullish sentiment (50-day avg)96%

Price to earnings ratio-10.3

Market capitalization799.3M

Earnings per share-0.58

Dividend yield (TTM)—

Revenue (annual)7.8M

Net income (annual)-64.9M

Social

What share of all stock conversation is about ACRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 16

Aclaris Therapeutics, Inc. (ACRS) received an "OVERWEIGHT" rating from Cantor, with a positive tone towards the company.
Traders are holding onto ACRS shares in hopes of a price rebound, with some taking profits and selling at $4 or lower.
Investors are expressing frustration and disappointment with ACRS' recent performance, with some labeling the company a "big POS" and others seeking a pump in price.

Generated by AI

Sentiment

Of the messages about ACRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.89% +30.27	85.37% -5.77
Bearish	—	—	11.11% -30.27	14.63% +5.77

Bullish· Jun 26

Aclaris Therapeutics, Inc. ($ACRS) is expected to break through its current resistance, with increasing trading volume and a clean chart pattern.
The stock is showing a strong potential for a breakout, with many traders closely monitoring its progress and anticipating a surge in price.
The company's technical indicators are looking favorable, with a clean and neat chart pattern, indicating a high likelihood of a successful breakout.

Bearish· Jan 10

$ACRS's lead product failed to meet expectations, and the company's shares dropped 25% due to disappointing results.
Aclaris Therapeutics was downgraded to Hold from Buy at Jefferies after the company reported topline data from its Phase 2b study of ATI-1777, which did not meet the firm's efficacy expectation benchmark.
The company's shares sank 18.75% after the company reported satisfactory results with its atopic dermatitis treatment, which may not be enough to justify the stock's price.

Generated by AI

Topics

Of the messages about ACRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	78.57%	62.22%
Technical Analysis	—	0%	0%	34%
Analysts	—	0%	21.43%	3.19%
Controversies	—	0%	0%	0.12%
Earnings	—	0%	0%	0.12%
Macro	—	0%	0%	0.35%

Earnings· Nov 7

Aclaris Therapeutics reported earnings that beat expectations by $0.23, but missed on revenue.
The company is scheduled to release earnings on November 7 before the market opens.
Aclaris Therapeutics' earnings report is causing investors to consider buying or selling the stock.

Analysts· Oct 22

Aclaris Therapeutics, Inc. ($ACRS) was upgraded to Outperform from Market Perform by SVB Leerink with a price target of $3.50.
The upgrade was based on the company's focus on early pipeline assets and near-term catalysts, including Phase 3 results for A-101 45% topical in common warts.
The price target was raised from $1.50 to $3.50, with analysts highlighting the company's potential for growth and increased value.

Announcements· Jan 20

Aclaris Therapeutics, Inc. (ACRS) has initiated a Phase 1b proof-of-concept trial for its novel bispecific antibody ATI-052 in atopic dermatitis, a key clinical catalyst.
The trial initiation has provided a strong fundamental catalyst for ACRS, with the stock surging to $4.76 +81.49% on major catalyst.
ACRS has decisively breached key resistances on massive trading volumes, confirming technical breakouts and fueling significant surges in the stock price.

Technical Analysis· Jan 20

$ACRS has broken key resistance levels on high volume, confirming technical breakouts and momentum.
The stock's Phase 1b trial news and catalysts, such as ATI-052, provide fundamental support for the move and are driving the technical momentum.
Measured technical targets project potential moves to $6.13, $7.96, $7.65, $7.36, $6.94, and $7.46, based on the stock's recent surges and breakouts.

Generated by AI

Community

Of the messages about ACRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	85.29%	73.8%
Newcomers	0%	0%	14.71%	26.2%

Regulars· Nov 19

Aclaris Therapeutics ($ACRS) has seen a significant increase in stock price, rising over 160% since the first mention in the TMM, with the latest big move being the agreement to license two immunology assets from Biosion.
Analysts have been upgrading their price targets for $ACRS, with BTIG and Jefferies both increasing their targets, and Leerink upgrading Aclaris to Outperform with a price target of $7, representing over 120% upside from current levels.
The company's cash-rich status and recent acquisitions, such as the transformative transaction for anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb, are being highlighted as key drivers of its continued growth and multiple upside scenarios.

Newcomers· Jun 26

The newcomers are focusing on Aclaris Therapeutics, Inc. ($ACRS) for a potential breakout, citing increasing trading volume and a clean chart pattern.
The traders are expecting a breakout from Aclaris Therapeutics, Inc. ($ACRS) based on its recent trading activity, which they believe is a positive sign.
The users are closely monitoring Aclaris Therapeutics, Inc. ($ACRS) for a breakout opportunity, noting its clean chart pattern and increasing trading volume.

Generated by AI

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

14d agoYahoo Finance

Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts

19d agoInvesting.com

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on

27d agoYahoo Finance UK

Canaccord initiates Aclaris stock with buy rating on pipeline potential

29d agoInvesting.com

Also Discussed

Investors talking about ACRS also mention

#	Name	Attention
1	RPHM - Reneo Pharmaceuticals, Inc.	——
2	ASLN - ASLAN Pharmaceuticals Limited	——
3	MRSN - Mersana Therapeutics, Inc.	——
4	Aptevo Therapeutics Inc.APVO	0%0
5	CHRA - Charah Solutions, Inc.	——
6	The Nightview FundNITE	0%0
7	GRTS - Gritstone bio, Inc.	——
8	KZR - Kezar Life Sciences, Inc.	——
9	Ares Commercial Real Estate CorporationACRE	0%new
10	OBLN - Obalon Therapeutics, Inc.	——

Aclaris Therapeutics, Inc.

Healthcare
Biotechnology

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small- and large-molecule therapies for immuno-inflammatory diseases. The company centers its work on conditions with significant unmet medical need, using its proprietary KINect drug discovery platform and integrated research capabilities to advance product candidates through early development. Aclaris Therapeutics’ portfolio includes therapeutics aimed at inflammatory and autoimmune disorders, with programs spanning dermatology-related conditions and other immune-mediated diseases. In addition to its core therapeutics business, the company operates a contract research segment through Confluence Discovery Technologies, which provides laboratory and drug discovery services to pharmaceutical and biotechnology partners. Based in Wayne, Pennsylvania, Aclaris Therapeutics plays a specialized role in the biopharmaceutical market by combining internal drug development with research services for external collaborators.

Website

Location

701 Lee Road

Wayne, PA, 19087

United States

Social

What share of all stock conversation is about ACRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 16

Aclaris Therapeutics, Inc. (ACRS) received an "OVERWEIGHT" rating from Cantor, with a positive tone towards the company.
Traders are holding onto ACRS shares in hopes of a price rebound, with some taking profits and selling at $4 or lower.
Investors are expressing frustration and disappointment with ACRS' recent performance, with some labeling the company a "big POS" and others seeking a pump in price.

Generated by AI

Sentiment

Of the messages about ACRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	88.89% +30.27	85.37% -5.77
Bearish	—	—	11.11% -30.27	14.63% +5.77

Bullish· Jun 26

Aclaris Therapeutics, Inc. ($ACRS) is expected to break through its current resistance, with increasing trading volume and a clean chart pattern.
The stock is showing a strong potential for a breakout, with many traders closely monitoring its progress and anticipating a surge in price.
The company's technical indicators are looking favorable, with a clean and neat chart pattern, indicating a high likelihood of a successful breakout.

Bearish· Jan 10

$ACRS's lead product failed to meet expectations, and the company's shares dropped 25% due to disappointing results.
Aclaris Therapeutics was downgraded to Hold from Buy at Jefferies after the company reported topline data from its Phase 2b study of ATI-1777, which did not meet the firm's efficacy expectation benchmark.
The company's shares sank 18.75% after the company reported satisfactory results with its atopic dermatitis treatment, which may not be enough to justify the stock's price.

Generated by AI

Topics

Of the messages about ACRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	78.57%	62.22%
Technical Analysis	—	0%	0%	34%
Analysts	—	0%	21.43%	3.19%
Controversies	—	0%	0%	0.12%
Earnings	—	0%	0%	0.12%
Macro	—	0%	0%	0.35%

Earnings· Nov 7

Aclaris Therapeutics reported earnings that beat expectations by $0.23, but missed on revenue.
The company is scheduled to release earnings on November 7 before the market opens.
Aclaris Therapeutics' earnings report is causing investors to consider buying or selling the stock.

Analysts· Oct 22

Aclaris Therapeutics, Inc. ($ACRS) was upgraded to Outperform from Market Perform by SVB Leerink with a price target of $3.50.
The upgrade was based on the company's focus on early pipeline assets and near-term catalysts, including Phase 3 results for A-101 45% topical in common warts.
The price target was raised from $1.50 to $3.50, with analysts highlighting the company's potential for growth and increased value.

Announcements· Jan 20

Aclaris Therapeutics, Inc. (ACRS) has initiated a Phase 1b proof-of-concept trial for its novel bispecific antibody ATI-052 in atopic dermatitis, a key clinical catalyst.
The trial initiation has provided a strong fundamental catalyst for ACRS, with the stock surging to $4.76 +81.49% on major catalyst.
ACRS has decisively breached key resistances on massive trading volumes, confirming technical breakouts and fueling significant surges in the stock price.

Technical Analysis· Jan 20

$ACRS has broken key resistance levels on high volume, confirming technical breakouts and momentum.
The stock's Phase 1b trial news and catalysts, such as ATI-052, provide fundamental support for the move and are driving the technical momentum.
Measured technical targets project potential moves to $6.13, $7.96, $7.65, $7.36, $6.94, and $7.46, based on the stock's recent surges and breakouts.

Generated by AI

Community

Of the messages about ACRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	85.29%	73.8%
Newcomers	0%	0%	14.71%	26.2%

Regulars· Nov 19

Aclaris Therapeutics ($ACRS) has seen a significant increase in stock price, rising over 160% since the first mention in the TMM, with the latest big move being the agreement to license two immunology assets from Biosion.
Analysts have been upgrading their price targets for $ACRS, with BTIG and Jefferies both increasing their targets, and Leerink upgrading Aclaris to Outperform with a price target of $7, representing over 120% upside from current levels.
The company's cash-rich status and recent acquisitions, such as the transformative transaction for anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb, are being highlighted as key drivers of its continued growth and multiple upside scenarios.

Newcomers· Jun 26

The newcomers are focusing on Aclaris Therapeutics, Inc. ($ACRS) for a potential breakout, citing increasing trading volume and a clean chart pattern.
The traders are expecting a breakout from Aclaris Therapeutics, Inc. ($ACRS) based on its recent trading activity, which they believe is a positive sign.
The users are closely monitoring Aclaris Therapeutics, Inc. ($ACRS) for a breakout opportunity, noting its clean chart pattern and increasing trading volume.

Generated by AI

Aclaris Therapeutics

Social

Sep 16

Bullish· Jun 26

Bearish· Jan 10

Earnings· Nov 7

Analysts· Oct 22

Announcements· Jan 20

Technical Analysis· Jan 20

Regulars· Nov 19

Newcomers· Jun 26

Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity

Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Canaccord initiates Aclaris stock with buy rating on pipeline potential

Also Discussed

Aclaris Therapeutics, Inc.

Company Information

Location

Cantor Fitzgerald reiterates Aclaris stock rating on LP opportunity

Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

Aclaris at Cantor Fitzgerald conference: pipeline, cash, catalysts

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Canaccord initiates Aclaris stock with buy rating on pipeline potential

Also Discussed

Social

Sep 16

Bullish· Jun 26

Bearish· Jan 10

Earnings· Nov 7

Analysts· Oct 22

Announcements· Jan 20

Technical Analysis· Jan 20

Regulars· Nov 19

Newcomers· Jun 26